MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

About this update from Maat Pharma

LYON, France, March 23, 2026 --( BUSINESS WIRE )--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer, today announced that Florent Malard, MD, PhD, hematology professor at Saint‑Antoine Hospital and Sorbonne University, presented the final results from the Phase 3 ARES single‑arm pivotal trial evaluating MaaT013 in acute Graft‑versus‑Host Disease (aGvHD). The presentation took place during the Presidential Plenary Session at the 2026 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Madrid, Spain. MaaT013 is currently under review by the European Medicines Agency (EMA) following the submission of a Marketing Authorization Application in June 2025, with a decision expected mid-2026, as previously disclosed. Professor Malard emphasized that "gastrointestinal acute GvHD remains a profoundly devastating condition, associated with dismal outcomes. The response rates observed in the ARES trial—62% GI-ORR at Day 28, sustained at 47% at Day 56 and 44% at Month 3—together with a 54% one-year overall survival, strongly suggest that this therapeutic approach may provide a clinically meaningful benefit for these patients." The final efficacy results from the ARES study, previously disclosed in December 2025 , are summarized below. The ARES trial is a single-arm, open label trial evaluating MaaT013 as third-line treatment in 66 adult patients with severe GI-aGvHD refractory to corticosteroids and ruxolitinib across 50 sites in six European countries: Patient profile: Final Efficacy Outcomes: The ARES trial results have been submitted to a peer-review leading medical journal for potential publication and will also be presented during an oral presentation by Professor Malard on March 27, 2026, during the annual congress of the French Society of Hematology in Paris. In addition to the oral presentation, MaaT Pharma presents three poster communications, during the EBMT Congress: PHOEBUS CHRONOS THRASSA --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aimed at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. About MaaT013 (Xervyteg®) MaaT Pharma’s Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. MaaT013 (brand name Xervyteg®) is currently under regulatory review by the relevant authorities and has not yet received marketing authorization. MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem Therapy TM for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of Butycore TM (a group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal (GI)-aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). About MaaT033 MaaT033, a standardized, donor-derived, high-richness, high-diversity oral Microbiome Ecosystem Therapy TM containing anti-inflammatory Butycore TM species, is currently being developed as an adjunctive therapy seeking to improve overall survival in patients receiving HSCT and other cellular therapies. Its aim is to seek to optimize microbiota function and to address a larger patient population in a chronic setting. MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA). Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20260323897931/en/ Contacts MaaT Pharma – Investor Relations Eric Soyer Chief Financial Officer +33 4 28 29 14 00 [email protected] MaaT Pharma – Media Relations Pauline Richaud Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected] Catalytic Agency – U.S. Media Relations Heather Shea Media relations for MaaT Pharma +1 617-286-2013 [email protected]

View stock analysis, news, and events for Maat Pharma